Compare American Superconductor Corporation (AMSC) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Superconductor Corporation vs Enveric Biosciences Inc — how do they compare? American Superconductor Corporation trades at $35.55 (market cap $1.74B), while Enveric Biosciences Inc trades at $1.34 (market cap $5.44M). The key difference: American Superconductor Corporation is far larger — about 319.9× Enveric Biosciences Inc's market cap, and American Superconductor Corporation is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| AMSC | ENVB | |
|---|---|---|
Market Cap | $1.74B | $5.44M |
Sector | Technology | Health |
52-Week High | $66.68 | $17.40 |
52-Week Low | $25.95 | $1.28 |
Enterprise Value | $1.61B | $529.67K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.
The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.
ENVB trades at $1.35, down 5.59% today, with a bearish technical signal from moving averages. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
Outlook remains speculative with high financial risk due to negative ROE and ROA, but analyst consensus is 75% buy. Key risks include clinical trial outcomes and cash burn, while institutional interest is supported by a recent $13.9M private placement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
